A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies-Reference-Cited by-同舟云学术

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies

Published:2020-01 Issue: Volume:124 Page:15-24
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Guo Christina W.,Alexander Marliese^ORCID,Dib Youseph,Lau Peter K.H.,Weppler Alison M.,Au-Yeung George,Lee Belinda,Khoo Chloe,Mooney Don,Joshi Subodh B.,Creati Louise,Sandhu Shahneen

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations;Gong;J Immunother Canc,2018

2. Kinase-targeted cancer therapies: progress, challenges and future directions;Bhullar;Mol Cancer,2018

3. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade;Ebert;Immunity,2016

4. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

5. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma;Wilmott;Clin Cancer Res,2012

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis;Expert Review of Anticancer Therapy;2024-06-16

2. Case: A Case of pembrolizumab induced myocarditis and complete heart block;Journal of Community Hospital Internal Medicine Perspectives;2024-05-07

3. Prognostic value of cardiovascular magnetic resonance in immune checkpoint inhibitor‐associated myocarditis: A systematic review and meta‐analysis;Cancer Innovation;2024-04-15

4. Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology;Genes & Diseases;2024-03

5. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors;Cardio-Oncology;2024-01-11